Ubs Group Ag Aurinia Pharmaceuticals Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

A detailed history of Ubs Group Ag transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Ubs Group Ag holds 150,699 shares of AUPH stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
150,699
Previous 137,174 9.86%
Holding current value
$1.22 Million
Previous $783,000 41.0%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$5.32 - $7.33 $71,953 - $99,138
13,525 Added 9.86%
150,699 $1.1 Million
Q2 2024

Aug 13, 2024
SELL
$4.81 - $5.78 $305,954 - $367,654
-63,608 Reduced 31.68%
137,174 $783,000
Q1 2024

May 13, 2024
SELL
$4.93 - $9.31 $259,840 - $490,692
-52,706 Reduced 20.79%
200,782 $1.01 Million
Q4 2023

Feb 09, 2024
BUY
$7.13 - $9.49 $437,111 - $581,793
61,306 Added 31.9%
253,488 $2.28 Million
Q3 2023

Nov 09, 2023
SELL
$7.77 - $12.27 $389,960 - $615,806
-50,188 Reduced 20.71%
192,182 $1.49 Million
Q2 2023

Aug 11, 2023
BUY
$8.96 - $11.69 $993,672 - $1.3 Million
110,901 Added 84.36%
242,370 $2.35 Million
Q1 2023

May 12, 2023
BUY
$5.94 - $11.27 $504,377 - $956,958
84,912 Added 182.38%
131,469 $1.44 Million
Q4 2022

Feb 08, 2023
BUY
$4.11 - $8.14 $40,409 - $80,032
9,832 Added 26.77%
46,557 $201,000
Q3 2022

Nov 10, 2022
SELL
$6.66 - $12.39 $754,531 - $1.4 Million
-113,293 Reduced 75.52%
36,725 $276,000
Q2 2022

Aug 10, 2022
SELL
$8.95 - $12.8 $228,663 - $327,027
-25,549 Reduced 14.55%
150,018 $1.51 Million
Q1 2022

May 16, 2022
BUY
$10.05 - $22.48 $620,899 - $1.39 Million
61,781 Added 54.3%
175,567 $2.17 Million
Q4 2021

Feb 14, 2022
SELL
$17.78 - $33.08 $2.2 Million - $4.1 Million
-123,943 Reduced 52.14%
113,786 $2.6 Million
Q3 2021

Nov 15, 2021
SELL
$10.93 - $23.55 $245,662 - $529,309
-22,476 Reduced 8.64%
237,729 $5.26 Million
Q2 2021

Aug 13, 2021
BUY
$10.0 - $14.52 $53,730 - $78,015
5,373 Added 2.11%
260,205 $3.37 Million
Q1 2021

May 12, 2021
BUY
$12.3 - $18.73 $476,612 - $725,768
38,749 Added 17.93%
254,832 $3.31 Million
Q4 2020

Feb 11, 2021
BUY
$12.94 - $16.05 $605,164 - $750,610
46,767 Added 27.62%
216,083 $2.99 Million
Q3 2020

Nov 12, 2020
BUY
$13.19 - $16.66 $890,773 - $1.13 Million
67,534 Added 66.35%
169,316 $2.49 Million
Q2 2020

Jul 31, 2020
SELL
$14.12 - $18.33 $291,154 - $377,964
-20,620 Reduced 16.85%
101,782 $1.65 Million
Q1 2020

May 01, 2020
BUY
$11.34 - $21.46 $447,272 - $846,425
39,442 Added 47.54%
122,402 $1.78 Million
Q4 2019

Feb 14, 2020
BUY
$3.88 - $21.42 $294,515 - $1.63 Million
75,906 Added 1076.07%
82,960 $1.68 Million
Q3 2019

Nov 14, 2019
BUY
$5.34 - $6.59 $3,262 - $4,026
611 Added 9.48%
7,054 $38,000
Q2 2019

Aug 14, 2019
SELL
$6.05 - $6.75 $3,515 - $3,921
-581 Reduced 8.27%
6,443 $42,000
Q1 2019

May 14, 2019
SELL
$6.06 - $7.64 $7,017 - $8,847
-1,158 Reduced 14.15%
7,024 $46,000
Q4 2018

Feb 14, 2019
SELL
$5.08 - $6.83 $613,603 - $824,982
-120,788 Reduced 93.66%
8,182 $55,000
Q3 2018

Nov 14, 2018
BUY
$5.27 - $6.64 $44,979 - $56,672
8,535 Added 7.09%
128,970 $857,000
Q2 2018

Aug 14, 2018
BUY
$5.06 - $6.36 $25,299 - $31,800
5,000 Added 4.33%
120,435 $678,000
Q1 2018

May 15, 2018
SELL
$4.85 - $5.99 $16,490 - $20,366
-3,400 Reduced 2.86%
115,435 $599,000
Q4 2017

Feb 14, 2018
BUY
$4.53 - $7.09 $117,780 - $184,340
26,000 Added 28.01%
118,835 $538,000
Q3 2017

Nov 14, 2017
SELL
$5.71 - $6.9 $32,575 - $39,364
-5,705 Reduced 5.79%
92,835 $582,000
Q2 2017

Aug 14, 2017
SELL
N/A
-13,774 Reduced 12.26%
98,540 $604,000
Q1 2017

Nov 14, 2017
BUY
N/A
112,314
112,314 $824,000

Others Institutions Holding AUPH

# of Institutions
209
Shares Held
58.7M
Call Options Held
1.14M
Put Options Held
1.51M
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email